Get informed when a big investor buys or sells
+ FollowOvervalued by 183.1% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $756.30 Million |
|---|---|
| Enterprise Value | $798.78 Million |
| Earnings per Share | $-0.01 |
| Beta | 0.83 |
| Outstanding Shares | 5,224,773,000 |
| P/E Ratio | -1.5 |
|---|---|
| PEG | -15.78 |
| Price to Sales | - |
| Price to Book Ratio | -0.15 |
| Enterprise Value to Revenue | 6.42 |
| Enterprise Value to EBIT | -11.22 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | -6.46 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, ...